Abstract: An alloy member includes a base member that includes a recess in a surface of the base member and is constituted by an alloy material containing chromium, an anchor portion is disposed in the recess and contains an oxide containing manganese and a covering layer is connected to the anchor portion and contains a low-equilibrium oxygen pressure element whose equilibrium oxygen pressure is lower than that of chromium.

Abstract: Disclosed are: a novel purine derivative, a composition thereof, a method for treating tumor using the purine derivative, and an antitumor agent using the purine derivative. Specifically disclosed is a compound represented by formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, or a prodrug thereof.

Abstract: Disclosed is an antidepressant, neuroprotectant, amyloid ? deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):

Abstract: Disclosed is an antidepressant, neuroprotectant, amyloid ? deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):

Abstract: A fracture splitting jig is fitted into a crank pin hole of a connecting rod, and a fracture load is applied in a longitudinal direction of the connecting rod via the fracture splitting jig to thereby fracture a big end of the connecting rod. A mandrel as the fracture splitting jig is divided into four parts to be separable from each other in a longitudinal direction of the connecting rod and in a direction orthogonal to the longitudinal direction. When the big end is fractured, a fractured portion thereof is allowed to come in contact with a predetermined portion of the fracture splitting jig.

Abstract: [Problem] To provide a prophylactic/therapeutic agent against, for example, nerve diseases and the like such as ischemic brain disease and neurodegenerative disease, or a prophylactic/therapeutic agent against diseases against which antioxidant action is effective, as a cell protecting agent, in particular as an inhibitor of brain cell damage or brain cell death.

Abstract: The connecting rod as a vehicle engine component is manufactured by a connecting rod fracture splitting method. The connecting rod is provided with a large end portion, a small end portion and a rod portion connecting the large and small end portions, the large end portion being provided with a connecting rod body and a cap which are split from each other along a fracture-split surface formed thereto. The connecting rod is subjected to fracture splitting by inserting a large end-side shaft into a through hole formed in the large end portion, fixing the large end-side shaft to a large end-side support, inserting a small end-side shaft into a through hole formed in the small end portion, fixing the small end-side shaft to a small end-side support, and pulling at least one of the large end-side support and small end-side support away from another one of both the supports.

Abstract: A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.

Abstract: Disclosed are: a novel purine derivative, a composition thereof, a method for treating tumor using the purine derivative, and an antitumor agent using the purine derivative. Specifically disclosed is a compound represented by formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, or a prodrug thereof.

Abstract: A kit, composition, product or medicament for treating cognitive impairment is provided, which includes a therapeutic agent for neurodegenerative disease and a heterocyclic compound represented by the following General Formula (I): or a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.

Abstract: A fracture splitting jig is fitted into a crank pin hole of a connecting rod, and a fracture load is applied in a longitudinal direction of the connecting rod via the fracture splitting jig to thereby fracture a big end of the connecting rod. A mandrel as the fracture splitting jig is divided into four parts to be separable from each other in a longitudinal direction of the connecting rod and in a direction orthogonal to the longitudinal direction. When the big end is fractured, a fractured portion thereof is allowed to come in contact with a predetermined portion of the fracture splitting jig.

Abstract: [Problem] To provide a prophylactic/therapeutic agent against, for example, nerve diseases and the like such as ischemic brain disease and neurodegenerative disease, or a prophylactic/therapeutic agent against diseases against which antioxidant action is effective, as a cell protecting agent, in particular as an inhibitor of brain cell damage or brain cell death.

Abstract: A kit, composition, product or medicament for treating cognitive impairment is provided, which includes a therapeutic agent for neurodegenerative disease and a heterocyclic compound represented by the following General Formula (I): or a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are a fuel cell and a voltage supply method which are designed to supply power to various electric circuits in a stable manner. The fuel cell of stack structure with output terminals attached to different generating elements as mentioned above produces a potential across the output electrodes which corresponds to the number of generating cells connected in series. The output terminals are connected respectively to the potential regulators varying in the allowable voltage range and the ratio of voltage conversion. A large output voltage is obtained if the generating units are connected in series, and a large output current is obtained if the generating units are connected in parallel. Thus the fuel cell can supply an adequate amount of power in response to load operation.

Abstract: Heterocyclic compounds represented by the formula I and anti-malignant-tumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Y represents C1-C6 alkyl; R1 represents morpholino (which may be substituted with one to four C1-C6 alkyl); and R2 and R3 each represent hydrogen atom or C1-C6 alkyl.

Abstract: A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.

Abstract: Heterocyclic compound represented by the formula I wherein represents or the like; R1 represents hydrogen atom, C1-C6 alkyl or benzyloxy; R2 represents methyl or nil; R3 represents hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R5 [wherein R5 represents phenyl (which may be substituted with C1-C6 alkyl, halogen atom or cyano)] or thienyl; R4 represents C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R6 [wherein R6 represents phenyl (which may be substituted with C1-C6alkyl, halogen atom or cyano), naphtyl or thienyl]; or R3 is coupled with R4.

Abstract: A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is disclosed. A novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is also disclosed.

Abstract: Disclosed is an method of treating cognitive impairment, including administering to a subject in need thereof a combination of a therapeutic agent for neurodegenerative disease and a therapeutically effective amount of a heterocyclic compound represented by the following general formula (I):

Abstract: Heterocyclic compounds represented by the formula I and anti-malignant-tumor agents containing the heterocyclic compounds as effective components: wherein X represents nitrogen atom or CH; Y represents C1-C6 alkyl; R1 represents morpholino (which may be substituted with one to four C1-C6 alkyl); and R2 and R3 each represent hydrogen atom or C1-C6 alkyl.